Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis
Abstract
Aim: To indirectly compare the efficacy and safety of elafibranor and seladelpar, as second-line treatments for primary biliary cholangitis. Materials & methods: Bayesian network meta-analyses compared data from randomized-controlled studies of elafibranor and seladelpar identified by a systematic literature review up to June 2024: (a) elafibranor (n = 108) versus placebo (n = 53; ELATIVE [ NCT04526665 ]) and (b) seladelpar (n = 128) versus placebo (n = 65; RESPONSE [ NCT03301506 ]). Patients from ELATIVE not meeting the RESPONSE upper limit of normal (ULN) criteria for alkaline phosphatase (ALP) and total bilirubin were excluded (n = 16); summary statistics for ELATIVE were recalculated using the new dataset. Random-effects models assessed the outcomes of cholestasis response (ALP
Fields of Study & Subjects
Liver Diseases and Immunity
Gallbladder and Bile Duct Disorders
Drug Transport and Resistance Mechanisms
Publication details
- Journal / source
- Journal of Comparative Effectiveness Research
- Publisher
- Becaris Publishing Limited
- Volume
- 15
- Issue
- 5
- Pages
- e250206–e250206
- Publication date
- 17 April 2026
- Language
- EN